Bupropion extended-release for depressive disorders

References

• Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry62, 617–627 (2005).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, Jin R, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry62, 593–602 (2005).
   PubMed Web of Science ®Google Scholar
• Conway KP, Comptom W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry67, 247–257 (2006).
   PubMed Web of Science ®Google Scholar
• Alonso J, Lépine J-P. Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMed). J. Clin. Psychiatry68(Suppl. 2), 3–9 (2007).
   PubMed Web of Science ®Google Scholar
• Laursen TM, Munk-Olsen T, Nordetoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J. Clin. Psychiatry68, 899–907 (2007).
   PubMed Web of Science ®Google Scholar
• Ösby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry58, 844–850 (2001).
   PubMed Web of Science ®Google Scholar
• Stahl SM. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int. J. Neuropsychopharmacol.10, 575–578 (2007).
   PubMed Web of Science ®Google Scholar
• Mehta NB. The chemistry of bupropion. J. Clin. Psychiatry44(Sec. 2), 56–59 (1983).
   PubMedGoogle Scholar
• Mehta DK, Aronson JK. Give a drug a good name. Lancet369, 1326–1328 (2007).
   PubMedGoogle Scholar
• Ferris RM, Cooper BR, Maxwell RA. Studies of bupropion’s mechanism of antidepressant activity. J. Clin. Psychiatry44(Sec. 2), 74–78 (1983).
   PubMed Web of Science ®Google Scholar
• Fabre LF, McLendon D, Mallette A. A double blind trial of bupropion hydrochloride – a novel antidepressant. Clin. Pharmacol. Ther.21, 102 (1977).
   Google Scholar
• Horne RL, Ferguson JM, Pope HG et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J. Clin. Psychiatry49, 262–266 (1988).
   PubMed Web of Science ®Google Scholar
• Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert. Rev. Neurotherapeutics6(9), 1249–1265 (2006).
   PubMed Web of Science ®Google Scholar
• Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J. Pharmacol. Exp. Ther.289(2), 877–885 (1999).
   PubMedGoogle Scholar
• Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J. Clin. Psychiatry64(Suppl. 13), 5–12 (2003).
   PubMed Web of Science ®Google Scholar
• Damaj MI, Carroll FI, Eaton JB et al. Enantioselective effects of hydroxyl metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol. Pharmacol.66, 675–682 (2004).
   PubMed Web of Science ®Google Scholar
• Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacolgy163, 102–105 (2002).
   PubMed Web of Science ®Google Scholar
• Learned-Coughlin SM, Bergström M, Savitcheva I, Ascher J, Schmith VD. The in vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol. Psychiatry54, 800–805 (2003).
   PubMed Web of Science ®Google Scholar
• El Mansari M, Ghanbari R, Janssen S, Blier P. Effects of long-term treatment with bupropion on the firing activity of serotonin and norepinephrine neurons. Eur. Neuropsychopharmacol.17(Suppl. 4), S173–S638 (2007).
   Google Scholar
• Rau KS, Birdsall E, Hanson JE et al. Bupropion increases striatal vesicular monoamine transport. Neuropharmacology49, 820–830 (2005).
   PubMed Web of Science ®Google Scholar
• Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin. Ther.27, 1685–1695 (2005).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Klein C, Meineke I et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics13(10), 619–626 (2003).
   PubMedGoogle Scholar
• Clayton AH. Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity? Expert. Opin. Pharmacother.8(4), 457–466 (2007).
   PubMed Web of Science ®Google Scholar
• Thase ME, Haight BR, Richard N et al. Emission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J. Clin. Psychiatry66, 974–981 (2005).
   PubMed Web of Science ®Google Scholar
• Clayton AH, Croft HA, Horrigan JP et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J. Clin. Psychiatry67, 736–746 (2006).
   PubMed Web of Science ®Google Scholar
• Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between bupropion XL and venlafaxine XR. J. Clin. Psychopharmacol.26, 482–488 (2006).
   PubMed Web of Science ®Google Scholar
• Chrzanowski W, Rousseau R, Hewett K et al. Efficacy and safety of bupropion extended release in elderly patients with major depressive disorder. Eur. Neuropsychopharmacol.16(Suppl. 4), S315 (2006).
   Google Scholar
• Jefferson JW, Rush AJ, Nelson JC et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry67, 865–873 (2006).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Nutt DJ, Hallett LA, Rucker VL, Krishen A, Fava M. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol. Psychiatry60, 1350–1355 (2006).
   PubMed Web of Science ®Google Scholar
• Wellbutrin XL® Prescribing Information. GlaxoSmithKline, Research Triangle Park, NC (2007).
   Google Scholar
• Modell JG, Rosenthal NE, Harriett AE et al. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol. Psychiatry58, 658–667 (2005).
   PubMed Web of Science ®Google Scholar
• Zimmerman M, Posternak M, Friedman M et al. Which factors influence psychiatrists’ selection of antidepressants? Am. J. Psychiatry161(7), 1285–1289 (2004).
   PubMed Web of Science ®Google Scholar
• Weihs KL, Houser TL, Batey SR et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol. Psychiatry51(9), 753–671 (2002).
   PubMed Web of Science ®Google Scholar
• Zimmerman M, Posternak MA, Attiullah N et al. Why isn’t bupropion the most frequently prescribed antidepressant? J. Clin. Psychiatry55, 603–610 (2005).
   Google Scholar
• Thase ME, Haight BR, Modell JG, Rockett CB, Asgharian A. Lack of effect of bupropion sustained release on blood pressure in hypertensive patients. Proceedings of 156th American Psychiatric Association Meeting. San Francisco, May 17–22, CA, USA, NR841 (2003).
   Google Scholar
• Kotlyar M, Brauer LH, Tracy TS et al. Inhibition of CYP2D6 activity by bupropion. J. Clin. Psychopharmacol25, 226–229 (2005).
   PubMed Web of Science ®Google Scholar
• Hays JT, Ebbert JO. Bupropion for the treatment of tobacco dependence. CNS Drugs17(2), 71–83 (2003).
   PubMed Web of Science ®Google Scholar
• Wilens TE, Haight BR, Horrigan JP et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol. Psychiatry57, 793–801 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O’Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes. Res.10(7), 633–641 (2002).
   PubMedGoogle Scholar
• Sachs GS, Lafer B, Stoll AL et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J. Clin. Psychiatry55(9), 391–393 (1994).
   PubMed Web of Science ®Google Scholar
• Sachs GS, Nierenberg AA, Calabrese JR et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N. Engl. J. Med.356, 1711–1722 (2007).
   PubMed Web of Science ®Google Scholar
• Post RM, Altshuler LL, Leverich GS et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br. J. Psychiatry189, 124–131 (2006).
   PubMed Web of Science ®Google Scholar
• Semenchuk MR, Sherman S, David B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology57, 1583–1588 (2001).
   PubMed Web of Science ®Google Scholar
• Bystritsky A, Kerwin L, Vapnik T. A pilot controlled trial of bupropion versus escitalopram in GAD. Proceedings of the 159th American Psychiatric Association Meeting. May 20, Toronto, Canada, NR638 (2006).
   Google Scholar
• DeBattista C, Solvason B, Poirier J, Kendrick E, Loraas E. A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J. Clin. Psychiatry66, 844–848 (2005).
   PubMed Web of Science ®Google Scholar
• Masand PS, Ashton AK, Gupta S, Frank B. Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study. Am. J. Psychiatry158(5), 805–807 (2001).
   PubMed Web of Science ®Google Scholar
• Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J. Clin. Psychiatry65, 62–67 (2004).
   PubMed Web of Science ®Google Scholar
• Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MBP. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-α and interferon-γ in mice. Int. Immunopharmacol.6, 903–907 (2006).
   PubMed Web of Science ®Google Scholar
• Stang P, Young S, Hogue S. Better patient persistence with once-daily bupropion compared with twice-daily bupropion. Am. J. Ther.14, 20–24 (2007).
   PubMedGoogle Scholar
• Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur. Neuropsychopharmacol.16, 391–402 (2006).
   PubMed Web of Science ®Google Scholar
• Nutt D, Demyttenaere K, Janka Z et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J. Psychopharmacol.21, 461–471 (2007).
   PubMed Web of Science ®Google Scholar
• Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry64, 327–337 (2007).
   PubMed Web of Science ®Google Scholar